ALK 201
Alternative Names: ALK-201Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Shanghai Allink Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 21 Nov 2024 US FDA approves IND application for ALK 201 in Solid tumours (ADNM)
- 26 Oct 2024 Preclinical trials in Solid tumours in China (IV)
- 26 Oct 2024 Shanghai Allink Biotherapeutics plans a phase I/II trial for Solid tumors (Late-stage disease) in October 2024 (NCT06656390)